
SECTION II. 510(K) SUMMARY

A. Device Name

Proprietary Name	Glidesheath
Classification Name	Introducer, Catheter
Common Name	Introducer Sheath

OCT 20 2006

B. Intended Use

The Glidesheath is used to facilitate placing a catheter through the skin into a vein or artery. The Mini Guide Wire is an accessory device which is used for placement of the sheath into the vein or artery. The RADIFOCUS Obturator is also an accessory device which is used by placing it into the sheath to create an occlusion and further provide support to the wall of the indwelling sheath while it remains in place within the vein or artery after removal of a catheter.

Note: This is the same intended use as the predicate device, Glidesheath K033681.

C. Device Description

The Glidesheath is comprised of an introducer sheath and a dilator.

The Glidesheath is used to facilitate placement of a catheter through the skin into a vein or artery. A Mini Guide Wire (with Inserter) may be included with the Glidesheath. The mini guide wire is available in a stainless steel or a nickel-titanium alloy polyurethane coated configuration. The Inserter does not contact blood and is used strictly for guiding the Guide Wire into a cannula or Introducer.

The A kit also contains a Surflo IV catheter, 2.5ml syringe, and scalpel for use in priming the system and gaining initial access to the vessel. Once access is obtained, the Mini Guide Wire is inserted through the cannula which was placed in the patient's blood vessel. The Glidesheath is then inserted over the Mini Guide Wire and into the blood vessel. The Mini Guide Wire is then withdrawn from the vessel. The Dilator maintains the integrity of the Sheath and dilates the blood vessel while the Glidesheath is being placed into the vessel. The Dilator can be removed and an appropriate catheter can then be inserted. The RADIFOCUS Obturator is an accessory device which creates an occlusion when inserted into the Sheath. The

Obturator also provides support to the indwelling Sheath after the catheter is removed.

The Sheath, Dilator and Obturator contain bismuth, making these devices visible under fluoroscopy.

D. Principle Of Operation / Technology

The Glidesheath and its accessories are operated manually or by a manual process.

E. Design / Materials

Differences in materials between the modified device and the predicate device the Glidesheath cleared under K033681 raise no new issues of safety and effectiveness.

F. Specifications

Part	Modified Glidesheath	Glidesheath cleared under K033681
Introducer Sheath Size Length	4, 5 & 6 French 10-25 cm	5 & 6 French 10-25 cm
Dilator Length	15.5 – 30.5 cm	15.5 – 30.5 cm
Guide Wire OD	0.021” – 0.038”	0.021” – 0.038”
Guide Wire Configurations	Stainless Steel or Nickel-Titanium alloy coated with Polyurethane	Stainless Steel
Accessory Devices	Obturator Surflo IV catheter Scalpel 2.5 ml Syringe	Obturator

G. Performance

The Glidesheath is comprised of an introducer sheath and a dilator. Only the introducer sheath was modified. The dilator was not modified. The nitinol mini guidewire is the same guidewire as the one cleared under K863138. The Surflo IV catheter (cleared under K891087), Syringe (cleared under K771205), and the RADIFOCUS Obturator (cleared under K954234) have not been modified. The scalpel is a class I exempted devices.

The following verification tests were performed to demonstrate the substantial equivalence of the modified device (Glidesheath) to the unmodified device (Glidesheath).

- Leakage/clogging
- Tensile strength of connections
- Separation force of dilator and sheath
- Internal sliding resistance
- External sliding resistance
- Penetration force

None of the data raises any new issues of safety and effectiveness. Additionally, a risk analysis was conducted and there were no new issues of safety and effectiveness.

Therefore the performance of the modified Glidesheath is substantially equivalent to the performance of the predicate device the Glidesheath which was cleared under K033681.

H. Additional Safety Information

Manufacturing controls include visual, functional, dimensional and sterility tests.

Blood contacting materials were tested in accordance with the tests recommended in the FDA General Program Memorandum #G95-1 (5/1/95): Use of International Standard ISO-10993, “Biological Evaluation of Medical Devices Part-1: Evaluation and Testing”.

The introducer sheath is classified as Externally Communicating Devices, Circulating Blood, Prolonged Contact (24 hrs to 30 days). Results of the testing demonstrate that the blood contacting materials are biocompatible.

Sterilization conditions have been validated in accordance with ANSI / AAMI / ISO 11135-1994, *Medical Devices – Validation and routine control of ethylene oxide sterilization* and EN 550. The device is sterilized to a SAL of 10^{-6} .

H. Substantial Equivalence

The modified Glidesheath is substantially equivalent in intended use, design, technology/principles of operation, materials and performance to the predicate device the Glidesheath, cleared under K033681. Differences between the two devices do not raise any significant issues of safety or effectiveness.

I. Submitter Information

Prepared By: Mr. Mark Unterreiner
Sr. Regulatory Affairs Specialist

Prepared For: Terumo Medical Corporation
950 Elkton Blvd.
Elkton, MD 21921
Phone: (410) 392-7213
Fax: (410) 398-6079
Email: mark.unterreiner@terumomedical.com

Date Prepared: September 22, 2006



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

OCT 20 2006

Terumo Medical Corporation
c/o Mr. Mark Unterreiner
Sr. Regulatory Affairs Specialist
950 Elkton Boulevard
Elkton, MD 21921

Re: K062858
Glidesheath
Regulation Number: 21 CFR 870.1340
Regulation Name: Catheter Introducer
Regulatory Class: II (two)
Product Code: DYB
Dated: September 22, 2006
Received: September 25, 2006

Dear Mr. Unterreiner:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

Danna R. Vochner

BZ

Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K062858

Device Name: Glidesheath

Indications For Use:

The Glidesheath is used to facilitate placing a catheter through the skin into a vein or artery. The Mini Guide Wire is an accessory device which is used for placement of the sheath into the vein or artery. The RADIFOCUS Obturator is also an accessory device which is used by placing it into the sheath to create an occlusion and further provide support to the wall of the indwelling sheath while it remains in place within the vein or artery after removal of a catheter.

Prescription Use X
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Diana R. Cochran
(Division Sign-Off)
Division of Cardiovascular Devices

510(k) Number K062858

00004